# US 2012/0251594 A1 · Delivery of Submicrometer and Nanometer Aerosols to the Lungs Using Hygroscopic Excipients or Dual Stream Nasal Delivery

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251594 A1
- Document ID: US20120251594A1
- Status: Published application
- Kind: A1
- Application number: 13/503,927
- Filed: 2010-11-09
- Published: 2012-10-04
- Earliest claimed: 2009-11-09
- Assignees: Virginia Commonwealth Univeristy
- Inventors: Philip Worth Longest; Michael Hindle
- Web page: https://patentgrep.com/patent/US20120251594A1

## CPC

- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 9/008: {comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]}
- A61K 9/12: Aerosols; Foams {(A61K9/0043, A61K9/0056, A61K9/006, A61K9/0073 take precedence; spray-films A61K9/7015)}
- A61K 9/5115: {Inorganic compounds}
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 31/58: containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin (digitoxin {A61K31/7048})
- A61M 11/001: {Particle size control}
- A61M 15/009: {using medicine packages with incorporated spraying means, e.g. aerosol cans (pocket atomiser of the injector type A61M11/08)}
- A61M 15/08: Inhaling devices inserted into the nose
- A61M 16/0057: {Pumps therefor}
- A61M 16/0666: {Nasal cannulas or tubing (devices for improving normal breathing through the nose A61F5/08; nose filters A62B23/06; outside holding devices A61M25/02)}
- A61M 16/0875: {Connecting tubes}
- A61M 16/109: {the humidifying liquid or the beneficial agent}
- A61M 16/147: {the respiratory gas not passing through the liquid container}
- A61M 16/16: Devices to humidify the respiration air {(A61M16/1045 takes precedence)}
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 23/00: Anaesthetics
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/24: Antidepressants
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61M 11/00: Sprayers or atomisers specially adapted for therapeutic purposes (in general B05B; {aerosol containers B65D83/14})
- A61M 11/005: {using ultrasonics (spraying or atomising liquids using ultrasonic vibrations in general B05B17/06)}
- A61M 15/00: Inhalators {(drug delivery in endotracheal tubes A61M16/04)}
- A61M 16/12: by mixing different gases
- A61M 16/20: Valves specially adapted to medical respiratory devices
- A61M 2202/0208: Oxygen
- A61M 2202/064: Powder
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Pharmaceutically engineered aerosols (e.g. submicrometer and nano-particles and droplets) containing a hygroscopic growth excipient or agent are employed to improve the delivery of respiratory aerosols to the lung. Inclusion of the hygroscopic agent results in near zero depositional loss in the nose-mouth-throat regions and near 100% deposition of the aerosol in the lung. Targeting of the aerosol to specific lung depths is also possible. In addition, methods and apparatuses for delivering aerosols to the lung are provided. The aerosol is delivered to one nostril of a patient while a relatively high humidity gaseous carrier is delivered to the other nostril, resulting in post-nasopharyngeal growth of the aerosol to a size that promotes deposition in the lung.

## Claims

### Claim 1

A submicrometer particle comprising
at least one active agent; and
at least one hygroscopic excipient associated with said at least one active agent, wherein
a hygroscopic parameter iexρex/Mex of said at least one hygroscopic excipient is at least 7 kmol/m3 and a growth coefficient iexρex/Mex·vfex+iaaρaa/Maa·vfaa of said submicrometer particle is at least 2.8; where
iex is the molecular dissociation constant of said at least one hygroscopic excipient,
iaa is the molecular dissociation constant of said at least one active agent,
ρex is the density of said at least one hygroscopic excipient,
ρaa is the density of said at least one active agent,
Mex is the molar mass of said at least one hygroscopic excipient, and
Maa is the molar mass of said at least one active agent.

### Claim 2 (depends on 1)

The submicrometer particle of claim 1, wherein said growth coefficient of said submicrometer particle is at least 5.

### Claim 3 (depends on 1)

The submicrometer particle of claim 1, wherein said growth coefficient of said submicrometer particle is at least 10.

### Claim 4 (depends on 1)

A powder suitable for use in a dry powder inhaler, said powder comprising the submicrometer particles of claim 1.

### Claim 5 (depends on 4)

The powder of claim 4, further comprising at least one pharmaceutical excipient.

### Claim 6

A suspension of submicrometer particles, comprising
i) submicrometer particles each of which comprises
at least one active agent; and
at least one hygroscopic excipient associated with said at least one active agent;
wherein
a hygroscopic parameter iexρex/Mex of said at least one hygroscopic excipient is at least 7 kmol/m3 and a growth coefficient iexρex/Mex·vfex+iaaρaa/Maa·vfaa of said submicrometer particles is at least 2.8; where
iex is the molecular dissociation constant of said at least one hygroscopic excipient,
iaa is the molecular dissociation constant of said at least one active agent,
ρex is the density of said at least one hygroscopic excipient,
ρaa is the density of said at least one active agent,
Mex is the molar mass of said at least one hygroscopic excipient, and
Maa is the molar mass of said at least one active agent; and
ii) a fluid, said submicrometer particles being distributed in said fluid.

### Claim 7 (depends on 6)

The suspension of claim 6, wherein said fluid comprises at least one liquefied propellant and wherein said suspension is suitable for use in a metered dose inhaler.

### Claim 8 (depends on 7)

The suspension of claim 7, wherein said at least one liquefied propellant is selected from the group consisting of hydrofluoroalkane, HFA 227 and HFA 134a.

### Claim 9 (depends on 6)

The suspension of claim 6, wherein said fluid comprises at least one aqueous solvent or at least one alcoholic solvent and wherein said suspension is suitable for use in a soft mist inhaler.

### Claim 10 (depends on 6)

The suspension of claim 6, wherein said growth coefficient of said submicrometer particle is at least 5.

### Claim 11 (depends on 6)

The suspension of claim 6, wherein said growth coefficient of said submicrometer particle is at least 10.

### Claim 12

A solution comprising at least one active agent, at least one hygroscopic excipient and at least one fluid,
wherein said active agent and said hygroscopic excipient are dissolved in said at least one fluid;
and wherein said solution is formulated such that it can be aerosolized to produce submicrometer particles or droplets, said submicrometer particles or droplets comprising said at least one active agent and said at least one hygroscopic excipient associated with said at least one active agent;
and wherein a hygroscopic parameter iexρex/Mex of said at least one hygroscopic excipient is at least 7 kmol/m3 and a growth coefficient iexρex/Mex·vfex+iaaρaa/Maa·vfaa of said submicrometer particles or droplets is at least 2.8; where
iex is the molecular dissociation constant of said at least one hygroscopic excipient,
iaa is the molecular dissociation constant of said at least one active agent,
ρex is the density of said at least one hygroscopic excipient,
ρaa is the density of said at least one active agent,
Mex is the molar mass of said at least one hygroscopic excipient, and
Maa is the molar mass of said at least one active agent.

### Claim 13 (depends on 12)

The solution of claim 12, wherein said at least one fluid includes at least one liquefied propellant and is suitable for use in a metered dose inhaler.

### Claim 14 (depends on 13)

The solution of claim 13, wherein said at least one liquefied propellant is selected from hydrofluoroalkane, HFA 227 and HFA 134a.

### Claim 15 (depends on 13)

The solution of claim 13, wherein said at least one fluid includes one or both of: i) at least one pharmaceutical excipient; and ii) at least one co-solvent.

### Claim 16 (depends on 15)

The solution of claim 15, wherein said at least one co-solvent is ethanol.

### Claim 17 (depends on 12)

The solution of claim 12, wherein said at least one fluid includes at least one aqueous solvent or at least one alcoholic solvent and is suitable for use in a soft mist inhaler.

### Claim 18 (depends on 17)

The solution of claim 17, wherein said at least one fluid includes one or both of i) at least one pharmaceutical excipient; and ii) at least one co-solvent.

### Claim 19 (depends on 18)

The solution of claim 18, wherein said at least one co-solvent is glycerol.

### Claim 20 (depends on 12)

The solution of claim 12, wherein said growth coefficient of said sub micrometer particle is at least 5.

### Claim 21 (depends on 12)

The solution of claim 12, wherein said growth coefficient of said submicrometer particle is at least 10.

### Claim 22

A method of targeted delivery of an active agent to a region of the respiratory system of a patient in need thereof, comprising
providing said active agent to said patient as aerosolized submicrometer particles or droplets which combine both
i) said active agent; and
ii) at least one hygroscopic excipient with a hygroscopic parameter isρs/Ms of at least 7 kmol/m3;
wherein said active agent and said at least one hygroscopic excipient are present in said aerosolized submicrometer particles or droplets in amounts sufficient to cause a predetermined amount of hygroscopic growth of said aerosolized submicrometer particles or droplets during passage through airways of said patient;
and wherein said aerosolized submicron particles or droplets have a growth coefficient iexρex/Mex·vfex+iaaρaa/Maa·vfaa of at least 2.8;
where
iex is the molecular dissociation constant of said at least one hygroscopic excipient,
iaa is the molecular dissociation constant of said at least one active agent,
ρex is the density of said at least one hygroscopic excipient,
ρaa is the density of said at least one active agent,
Mex is the molar mass of said at least one hygroscopic excipient, and
Maa is the molar mass of said at least one active agent.

### Claim 23 (depends on 22)

The method of claim 22, wherein said active agent is a medicament.

### Claim 24 (depends on 22)

The method of claim 22, wherein said active agent is a peptide.

### Claim 25 (depends on 22)

The method of claim 22, wherein said active agent is selected from the group consisting of agents for the treatment of asthma and other respiratory disorders, anesthesia agents, nucleic acid molecules, anti-pain agents, anti-inflammation agents, anti-depressants and other mood altering drugs, anti-viral agents, anti-bacterial agents, anti-fungal agents, anti-cancer agents, hormones, benzodiazepines and calcitonin.

### Claim 26 (depends on 22)

The method of claim 22, wherein said predetermined amount of hygroscopic growth is sufficient to cause targeted deposition of said aerosolized submicrometer particles or droplets in a region of said respiratory system of said patient selected from the group consisting of: nasal cavity, trachea, lung, alveolar airways, tracheobronchial airways, upper tracheobronchial airways, lower tracheobronchial airways, and lower tracheobronchial-alveolar airways.

### Claim 27 (depends on 22)

The method of claim 22, wherein said region of said respiratory system is the nasal cavity.

### Claim 28 (depends on 22)

The method of claim 22, wherein said region of said respiratory system is the trachea.

### Claim 29 (depends on 22)

The method of claim 22, wherein said region of said respiratory system is the lung.

### Claim 30 (depends on 22)

The method of claim 22, wherein said region of said respiratory system is the alveolar airways.

### Claim 31 (depends on 22)

The method of claim 22, wherein said region of said respiratory system is the tracheobronchial airways.

### Claim 32 (depends on 22)

The method of claim 22, wherein said region of said respiratory system is the lower tracheobronchial-alveolar airways.

### Claim 33

A method for making a particle- or droplet-forming solution which forms aerosol particles or droplets that are 1.5 micrometers or less in size, and which attract water when exposed to airways of a patient, comprising the step of
combining, in a fluid, an active agent and a hygroscopic excipient,
wherein said active agent and said hygroscopic excipient are present in said aerosol particles or droplets in amounts sufficient to cause a predetermined amount of hygroscopic growth of said aerosol particles or droplets during passage through said airways of said patient;
and wherein said aerosol particles or droplets have a growth coefficient iexρex/Mex·vfex+iaaρaa/Maa·vfaa of at least 2.8;
where
iex is the molecular dissociation constant of said at least one hygroscopic excipient,
iaa is the molecular dissociation constant of said at least one active agent,
ρex is the density of said at least one hygroscopic excipient,
ρaa is the density of said at least one active agent,
Mex is the molar mass of said at least one hygroscopic excipient, and
Maa is the molar mass of said at least one active agent.

### Claim 34 (depends on 33)

The method of claim 33, wherein said aerosol particles or droplets are initially submicrometer in size.

### Claim 35 (depends on 33)

The method of claim 33, wherein said hygroscopic excipient is added in said adding step in an amount sufficient to cause said aerosol particles or droplets to increase in size to at least 2 micrometers or above.

### Claim 36 (depends on 33)

The method of claim 33, wherein said hygroscopic excipient is added in said adding step in an amount sufficient to cause said aerosol particles or droplets to increase in size to at least 3 micrometers or above.

### Claim 37 (depends on 33)

The method of claim 33, wherein said hygroscopic excipient is added in said adding step in an amount sufficient to cause said aerosol particles or droplets to increase in size to at least 4 micrometers or above.

### Claim 38

A method of delivering aerosolized submicrometer particles or droplets to a region of a respiratory system of a patient in need thereof, comprising the steps of
delivering said aerosolized submicrometer particles or droplets in a first gaseous transport fluid into a first nostril of said patient; and
simultaneously delivering a second gaseous transport fluid into a second nostril of said patient;
wherein a water vapor content of said second gaseous transport fluid is greater than a water vapor content of said first gaseous transport fluid.

### Claim 39 (depends on 38)

The method of claim 38, wherein said first gaseous transport fluid has an initial temperature from 20° C. to 47° C. at a nasal inlet.

### Claim 40 (depends on 38)

The method of claim 38, wherein said second gaseous transport fluid has an initial temperature from 30° C. to 47° C. at a nasal inlet.

### Claim 41 (depends on 38)

The method of claim 38, wherein said first gaseous transport fluid has an initial relative humidity from 0 to 100% at a nasal inlet.

### Claim 42 (depends on 38)

The method of claim 38, wherein said second gaseous transport fluid has an initial relative humidity from 70 to 110% at a nasal inlet.

### Claim 43 (depends on 38)

The method of claim 38, wherein said submicrometer submicron particles or droplets comprise at least one therapeutic agent.

### Claim 44 (depends on 38)

The method of claim 38, further comprising the step of
adjusting a temperature and a water vapor content of said first gaseous transport fluid and a temperature and a water vapor content of said second gaseous transport fluid to cause a predetermined amount of hygroscopic growth of said aerosolized submicrometer particles or droplets during passage through said respiratory system of said patient.

### Claim 45 (depends on 44)

The method of claim 44, wherein said predetermined amount of hygroscopic growth is sufficient to cause targeted deposition of said aerosolized submicrometer particles or droplets in a region of said respiratory system of said patient selected from the group consisting of: nasal cavity, trachea, lung, alveolar airways, tracheobronchial airways, upper tracheobronchial airways, lower tracheobronchial airways, and lower tracheobronchial-alveolar airways.

### Claim 46

An apparatus for delivering an active agent as aerosolized submicrometer particles or droplets to the lung of a patient in need thereof, comprising
a first delivery line for delivering said active agent as aerosolized submicrometer particles or droplets in a first gaseous carrier fluid to a first nostril of said patient; and
a second delivery line for delivering a second gaseous carrier fluid which lacks said active agent to a second nostril of said patient.

### Claim 47 (depends on 46)

The apparatus of claim 46, further comprising means of adding water vapor to one or both of said first and second gaseous carrier fluids.

### Claim 48 (depends on 46)

The apparatus of claim 46, further comprising means of heating one or both of said first and second gaseous carrier fluids.
